ReviewTherapeutic advances in gastroenterology2021
Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives.
Review in Therapeutic advances in gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- ESR Essentials: diagnosis and assessment of treatment response in patients with luminal Crohn's disease-practice recommendations by the European Society of Gastrointestinal and Abdominal Radiology.European radiology · 2025Guideline
- Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement.Journal of Crohn's & colitis · 2022Pooled it
- Evaluating sonographic response and remission in inflammatory bowel disease: aligning intestinal ultrasound assessment with STRIDE-II timelines.Journal of Crohn's & colitis · 2026Review
- Early transmural response assessed by intestinal ultrasound predicts long-term clinical remission in patients with IBD: Results from the TRUST BEYOND study.Inflammatory bowel diseases · 2026Article
- Abbreviated non-contrast magnetic resonance enterography for Crohn's disease: a reliability study.La Radiologia medica · 2026Article
- Predictors of First Anti-TNF Treatment Failure in Patients with Inflammatory Bowel Disease: A Single-Center Cohort Study.Biomedicines · 2026Article
- Integrating Intestinal Ultrasound in the Personalized Management of IBD.Journal of personalized medicine · 2026Review
- Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial.BMJ open gastroenterology · 2026Article
- Translational photoacoustic and ultrasound imaging catheter for characterizing gastrointestinal inflammation and fibrosis: a study with a pig modelBiomedical optics express · 2026Article
- Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges.Inflammatory bowel diseases · 2025Review
- The Role of Imaging in Inflammatory Bowel Diseases: From Diagnosis to Individualized Therapy.Diagnostics (Basel, Switzerland) · 2025Review
- Mesenteric fat proliferation on magnetic resonance enterography is a predictor of long-term disease complications in crohn's disease.BMC gastroenterology · 2025Article
- [Imaging in chronic inflammatory bowel disease].Innere Medizin (Heidelberg, Germany) · 2025Review
- Validation of intestinal ultrasound scores in assessing endoscopic activity of colonic and small intestinal Crohn's disease in a southwest Chinese cohort: a retrospective cross-sectional study.Quantitative imaging in medicine and surgery · 2024Article
- Magnetic Resonance Enterography and Intestinal Ultrasound for the Assessment and Monitoring of Crohn's Disease.Journal of Crohn's & colitis · 2024Review
- Amino acid-based enteral nutrition is effective for pediatric Crohn's disease: a multicenter prospective study.Gastroenterology report · 2024Article
- Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing.Biomedicines · 2023Review
- Article
- Prognostic role of intestinal ultrasound in Crohn's disease.World journal of gastroenterology · 2023Review
- Bronchoesophageal fistula in a patient with Crohn's disease receiving anti-tumor necrosis factor therapy.Clinical endoscopy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment targets of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD) have evolved over the last decade. Goals of therapy consisting of symptom control and steroid sparing have shifted to control of disease activity with endoscopic remission being an important endpoint. Unfortunately, this requires ileocolonoscopy, an invasive procedure. Biomarkers [C-reactive protein (CRP) and fecal calprotectin (FCP)] have emerged as surrogates for endoscopic remission and disease activity, but also have limitations. Despite this evolution, we must not lose sight that CD involves transmural inflammation, not fully appreciated with ileocolonoscopy. Therefore, transmural assessment of disease activity by cross-sectional imaging, in particular with magnetic resonance enterography (MRE) and intestinal ultrasonography (IUS), is vital to fully understand disease control. Bowel-wall thickness (BWT) is the cornerstone in assessment of transmural inflammation and BWT normalization, with or without bloodflow normalization, the key element demonstrating resolution of transmural inflammation, namely transmural healing (TH) or transmural remission (TR). In small studies, achievement of TR has been associated with improved long-term clinical outcomes, including reduced hospitalization, surgery, escalation of treatment, and a decrease in clinical relapse over endoscopic remission alone. This review will focus on the existing literature investigating the concept of TR or residual transmural disease and its relation to other existing treatment targets. Current data suggest that TR may be the next logical step in the evolution of treatment targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.